Loading
Immuron Limited is a biopharmaceutical company focused on the discovery, development, and global commercialization of polyclonal antibodies, with operations spanning Australia, the United States, and other international markets. The company's activities are structured into two key segments: Research and Development, and Hyperimmune Products. Currently, Immuron markets two key products. Travelan is an over-the-counter (OTC) medicine that helps reduce the risk of traveler's diarrhea and lessens symptoms of minor gastrointestinal issues, while also serving as a dietary supplement for digestive tract protection. Its second product, Protectyn, is an immune supplement formulated to support healthy digestive function and liver health. In its pipeline, an advanced formulation of Travelan (IMM-124E) is undergoing Phase III clinical trials. This variant is being developed not only to further reduce the risk of traveler's diarrhea but also for its potential anti-viral activity against SARS-CoV-2. Another pipeline candidate, IMM-529, is in clinical development with a focus on treating recurrent Clostridium difficile infections. Immuron maintains strategic collaborations, including a research agreement with the Naval Medical Research Center to develop and clinically assess a therapeutic targeting Campylobacter and ETEC infections. Additionally, it has a collaboration with the Walter Reed Army Institute of Research aimed at creating an oral therapeutic for shigellosis. Established in 1994, Immuron Limited is headquartered in Carlton, Australia.
Previous close
$1.84
+$0.04 · +2.22%
Pre-market
$1.79
−$0.05 · -2.72%
Sep 9, 8:58 AM ET
Regular session · ET · Market data may be delayed.
Immuron Limited is a biopharmaceutical company focused on the discovery, development, and global commercialization of polyclonal antibodies, with operations spanning Australia, the United States, and other international markets. The company's activities are structured into two key segments: Research and Development, and Hyperimmune Products. Currently, Immuron markets two key products. Travelan is an over-the-counter (OTC) medicine that helps reduce the risk of traveler's diarrhea and lessens symptoms of minor gastrointestinal issues, while also serving as a dietary supplement for digestive tract protection. Its second product, Protectyn, is an immune supplement formulated to support healthy digestive function and liver health. In its pipeline, an advanced formulation of Travelan (IMM-124E) is undergoing Phase III clinical trials. This variant is being developed not only to further reduce the risk of traveler's diarrhea but also for its potential anti-viral activity against SARS-CoV-2. Another pipeline candidate, IMM-529, is in clinical development with a focus on treating recurrent Clostridium difficile infections. Immuron maintains strategic collaborations, including a research agreement with the Naval Medical Research Center to develop and clinically assess a therapeutic targeting Campylobacter and ETEC infections. Additionally, it has a collaboration with the Walter Reed Army Institute of Research aimed at creating an oral therapeutic for shigellosis. Established in 1994, Immuron Limited is headquartered in Carlton, Australia.
Day range
Current $1.84
52-week range
Current $1.84
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
72
Undervalued
Sentiment
53
Mixed
Risk
66
High Risk
Momentum
47
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Immuron Limited is a biopharmaceutical company focused on the discovery, development, and global commercialization of polyclonal antibodies, with operations spanning Australia, the United States, and other international markets. The company's activities are structured into two key segments: Research and Development, and Hyperimmune Products. Currently, Immuron markets two key products. Travelan is an over-the-counter (OTC) medicine that helps reduce the risk of traveler's diarrhea and lessens symptoms of minor gastrointestinal issues, while also serving as a dietary supplement for digestive tract protection. Its second product, Protectyn, is an immune supplement formulated to support healthy digestive function and liver health. In its pipeline, an advanced formulation of Travelan (IMM-124E) is undergoing Phase III clinical trials. This variant is being developed not only to further reduce the risk of traveler's diarrhea but also for its potential anti-viral activity against SARS-CoV-2. Another pipeline candidate, IMM-529, is in clinical development with a focus on treating recurrent Clostridium difficile infections. Immuron maintains strategic collaborations, including a research agreement with the Naval Medical Research Center to develop and clinically assess a therapeutic targeting Campylobacter and ETEC infections. Additionally, it has a collaboration with the Walter Reed Army Institute of Research aimed at creating an oral therapeutic for shigellosis. Established in 1994, Immuron Limited is headquartered in Carlton, Australia.
Day range
Current $1.84
52-week range
Current $1.84
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (AUD) | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | 7.55M AUD | 7.29M AUD | 4.9M AUD | 1.8M AUD | 765.19K AUD |
| Cost of goods sold | 2.68M AUD | 2.52M AUD | 1.57M AUD | 64.63K AUD | 241.69K AUD |
| Gross profit | 4.87M AUD | 4.77M AUD | 3.34M AUD | 1.74M AUD | 523.5K AUD |
| Research and development | — | 3.6M AUD | 5.38M AUD | 2.59M AUD | 657.72K AUD |
| Selling, general, and administrative | 7.61M AUD | 7.94M AUD | 6.59M AUD | 5.15M AUD | 3.94M AUD |
| Operating expenses | 9.5M AUD | 10.11M AUD | 9.14M AUD | 5.31M AUD | 3.39M AUD |
| Interest income | — | 135.87K AUD | 327.76K AUD | 116.32K AUD | 21.79K AUD |
| Interest expense | 14.39K AUD | 7.31K AUD | 7.58K AUD | 9.65K AUD | 6.18K AUD |
| Depreciation and amortization | — | 49.69K AUD | 45.98K AUD | 48.66K AUD | 26.61K AUD |
| Operating income | −4.63M AUD | −5.34M AUD | −5.8M AUD | −3.57M AUD | −2.87M AUD |
| Net income | −3.75M AUD | −5.22M AUD | −6.94M AUD | −3.79M AUD | −2.85M AUD |
Company facts updated Sep 9, 2026.
Recent quarterly results
Recent quarterly results
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
